When a seriously ill mature minor and his parent disagree about his receiving an experimental intervention, who should decide what treatment he will receive?
Though there are channels through which terminally ill patients can access some experimental drugs that have not yet received FDA approval for marketing to the public, in general those drugs must already be proven safe and effective.
In the September 2014 issue on physicians as agents of social change, Dr. Audiey Kao, editor-in-chief of Virtual Mentor interviewed Dr. Rajiv Shah, administrator of the United States Agency for International Development or USAID.
When a seriously ill mature minor and his parent disagree about his receiving an experimental intervention, who should decide what treatment he will receive?
Punishing women who use drugs during pregnancy deters them from seeking prenatal care and entering drug treatment programs, and the relevant policies may unfairly target poor or minority women.
Jessie Kimbrough-Sugick, MD, MPH, Jessica Holzer, MA, and Eric B. Bass, MD, MPH
Researchers who approach community partners with an agenda already in hand are missing the point of the community-based participatory research enterprise: developing priorities for study together.
By privileging traditional research methods in forms for research protocol approval, IRBs can unknowingly allow community partners to be harmed in CBPR. Changes to the language can help ensure appropriate sensitivity and community involvement.